Jason Westin, MD

Articles

Dr. Westin on Subgroup Analysis of ZUMA-7 of Elderly Patients With R/R DLBCL

June 6th 2022

Jason R. Westin, MD, discusses subgroup analysis of elderly patients treated in the ZUMA-7 trial.

Dr. Westin on the Evolving Landscape of CAR T-Cell Therapy in NHL

May 3rd 2022

Jason R. Westin, MD, discusses the evolving landscape of CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Westin on the Utilization of CAR T-Cell Therapy in LBCL

March 2nd 2022

Jason R. Westin, MD, director, discusses the utilization of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Concluding Thoughts on the DLBCL Treatment Landscape

February 24th 2022

DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.

Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

February 24th 2022

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.

Monoclonal Antibodies for Treatment of R/R DLBCL

February 17th 2022

Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.

Real-World Data With CAR-T Therapies in R/R DLBCL

February 17th 2022

Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.

Safety With CAR-T Therapies in R/R DLBCL

February 10th 2022

Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.

CAR-T Therapies in R/R DLBCL

February 10th 2022

Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.

CAR-T Therapy

February 3rd 2022

Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.

Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma

February 3rd 2022

Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.

Dr. Westin on Patient-Reported Outcomes From the TRANSFORM Study in R/R LBCL

January 24th 2022

Jason R. Westin, MD,discusses the patient-reported outcome data from the phase 3 TRANSFORM study in relapsed/ refractory large B-cell lymphoma.

Dr. Westin on the 2​-Year Follow-Up of the TRANSCEND-NHL-001 Trial in R/R LBCL

January 24th 2022

Jason R. Westin, MD, discusses the 2-year follow-up data of the ongoing phase 1 TRANSCEND-NHL-001 trial in relapsed/refractory large B-cell lymphoma.

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

January 24th 2022

A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.

Front-Line Treatment of DLBCL

January 24th 2022

Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

December 23rd 2021

A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.

Dr. Westin on Response Rates in the JULIET Trial for DLBCL

September 14th 2019

Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.